Sanofi has been actively expanding their portfolio and presence in the global market. Multiple pacts have been signed with GSK in pursuit of new antibody treatments for autoimmune disorders and cancers. The relevant drug proposals are under review by the FDA. In China, their Bleeding-Disorder Treatments have been approved, and equity investments have been raised from many sources including InduPro. The expansion of their vaccination line has received the critical nod from NMPA. However, Sanofi's financial activities have drawn attention, their headquarters in France was raided under suspicions of tax fraud. The denouncement by JPMorgan potentially added to their unpredictable stock movements. Progress in AI implementation seems to be a strong focus for Sanofi, with AI R&D in Drug Discovery garnering significant attention. Furthermore, partnerships have been developed to advance bispecific therapies for autoimmune disorders. Whilst patient-centric care is becoming a priority, Sanofi is embroiled in a lawsuit from Texas accusing BMS and them of concealing ineffective results from blood-thinner Plavix. A recent collaboration with Novavax could be a game-changer, and approvals in China for two of their rare disease medications have pushed their global expansion further.
Sanofi News Analytics from Thu, 03 Apr 2025 20:10:09 GMT to Sat, 13 Dec 2025 23:14:41 GMT -
Rating -4
- Innovation 2
- Information 8
- Rumor -6
